StephenJamesSimkoIIIMD

Pediatric Hematology & Oncology • Palo Alto, CA

Pediatric Hematologic Oncology

Senior Medical Director, Genentech; Adjunct Clinical Assistant Professor, Lucile Packard Children's Hospital/Stanford University

Join to view full profile

Dr. Simko is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Simko's full profile

Already have an account?

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8000

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2008 - 2011
University of ColoradoResidency, Pediatrics, 2004 - 2007
Medical College of Georgia at Augusta UniversityClass of 2004

Certifications & Licensure

CA State Medical License 2015 - 2025
TX State Medical License 2011 - 2015
OH State Medical License 2007 - 2010
CO State Medical License 2006 - 2009
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Start of enrollment: 2013 Jan 01
Terminated
Phase 1
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies Start of enrollment: 2013 Jan 01
Completed
Early Phase 1
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors Start of enrollment: 2016 May 20
Completed
Phase 1, Phase 2
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma Start of enrollment: 2020 Jun 04
Completed
Phase 1
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2021 Feb 23
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

288 citations
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Rikhia Chakraborty, Oliver A. Hampton, Xiaoyun Shen, Stephen J. Simko, Albert Shih
Blood. 2014-11-06
28 citations
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medi...
Andrew D.J. Pearson, C. Michel Zwaan, E. Anders Kolb, Dominik Karres, Julie Guillot
European Journal of Cancer. 2020-09-01
53 citations
Differentiating skin-limited and multisystem Langerhans cell histiocytosis
Stephen J. Simko, Benjamin Garmezy, Harshal Abhyankar, Philip J. Lupo, Rikhia Chakraborty
The Journal of Pediatrics. 2014-11-01